These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16793989)

  • 1. Renal safety of gadolinium-based contrast agent for ionizing radiation imaging.
    Becker J; Thompson H
    Radiology; 2006 Jul; 240(1):301-2; author reply 302. PubMed ID: 16793989
    [No Abstract]   [Full Text] [Related]  

  • 2. Gadolinium-based contrast media for multi-detector row spiral CT pulmonary angiography in patients with renal insufficiency.
    Morcos SK; Remy-Jardin M
    Radiology; 2006 Mar; 238(3):1077; author reply 1077-8. PubMed ID: 16505405
    [No Abstract]   [Full Text] [Related]  

  • 3. [Gadolinium: a true problem for the nephrologists?].
    Balducci A; Tamburrini O
    G Ital Nefrol; 2008; 25(1):3-4. PubMed ID: 18264906
    [No Abstract]   [Full Text] [Related]  

  • 4. Gadolinium use in patients with kidney disease: a cause for concern.
    Perazella MA; Rodby RA
    Semin Dial; 2007; 20(3):179-85. PubMed ID: 17555477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?
    Thomsen HS; Marckmann P; Logager VB
    Acta Radiol; 2007 Jul; 48(6):593-6. PubMed ID: 17611863
    [No Abstract]   [Full Text] [Related]  

  • 6. Gadolinium-based contrast agents and nephrotoxicity.
    Morcos SK
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):812; author reply 813. PubMed ID: 17039541
    [No Abstract]   [Full Text] [Related]  

  • 7. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia?
    Nyman U; Elmståhl B; Leander P; Nilsson M; Golman K; Almén T
    Radiology; 2002 May; 223(2):311-8; discussion 328-9. PubMed ID: 11997530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nephrogenic systemic fibrosis].
    Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
    G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?
    Perazella MA
    Clin J Am Soc Nephrol; 2008 May; 3(3):649-51. PubMed ID: 18385396
    [No Abstract]   [Full Text] [Related]  

  • 10. Suggesting gadolinium-based contrast media for CT in azotemic patients is not based on historical, clinical, and experimental data.
    Nyman U; Elmståhl B; Leander P
    Radiology; 2007 Aug; 244(2):622-3. PubMed ID: 17641384
    [No Abstract]   [Full Text] [Related]  

  • 11. Gadolinium chelates in angiography and interventional radiology: a useful alternative to iodinated contrast media for angiography.
    Spinosa DJ; Kaufmann JA; Hartwell GD
    Radiology; 2002 May; 223(2):319-25; discussion 326-7. PubMed ID: 11997531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium contrast may be risky in kidney disease.
    Thomson PC; Collidge TA; Mark PB; Traynor JP
    BMJ; 2007 Jun; 334(7608):1335-6. PubMed ID: 17599982
    [No Abstract]   [Full Text] [Related]  

  • 14. [Using low osmolar gadolinium for angiographic imaging and in interventional radiologic procedures in patients with renal failure].
    Strunk H
    Rofo; 2003 Apr; 175(4):571; author reply 571-2. PubMed ID: 12741405
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 17. Renal failure and gadolinium. The number of documented cases is rising.
    Prescrire Int; 2008 Oct; 17(97):205. PubMed ID: 19537311
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and effectiveness of gadolinium-enhanced multi-detector row spiral CT angiography of the chest: preliminary results in 37 patients with contraindications to iodinated contrast agents.
    Remy-Jardin M; Dequiedt P; Ertzbischoff O; Tillie-Leblond I; Bruzzi J; Duhamel A; Remy J
    Radiology; 2005 Jun; 235(3):819-26. PubMed ID: 15845797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A word of caution on the use of high-dose MR contrast media in patients with renal failure.
    Geckeis K; Eggebrecht H; Quick HH; Barkhausen J; Kribben A; Erbel R
    J Endovasc Ther; 2005 Apr; 12(2):262. PubMed ID: 15823076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.